论文部分内容阅读
目的观察新辅助放化疗对食管癌患者肺功能的影响,以及对术后肺部并发症的影响。方法回顾性分析医院2012年1月-2013年7月术前行放化疗的64例食管癌患者,观察患者放化疗前后肺功能变化和肺部并发症发生情况。结果放化疗后肺功能一氧化碳弥散量(DLCO)较放化疗前明显降低,差异有统计学意义(P<0.05)。而用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、1秒率(FEV1/FVC)、肺活量(VC)、DLCO、最大自主通气量(MVV)、残气量(RC)及最大呼气中段流量(MMEF)等肺功能指标均未见明显变化。结论对食管癌患者进行放化疗可降低肺弥散功能,对肺部其分功能无明显影响,且不会增加患者术后肺部并发症的发生。
Objective To observe the effects of neoadjuvant radiochemotherapy on lung function in patients with esophageal cancer and its effect on postoperative pulmonary complications. Methods A retrospective analysis was performed on 64 patients with esophageal cancer who underwent chemoradiotherapy during January 2012 to July 2013 in our hospital. The changes of lung function and pulmonary complications before and after chemoradiotherapy were observed. Results After radiotherapy and chemotherapy, the diffused amount of pulmonary function carbon monoxide (DLCO) was significantly lower than that before radiotherapy and chemotherapy, the difference was statistically significant (P <0.05). FVC, FEV 1, FEV 1 / FVC, VC, DLCO, MVV, RC and maximal respiratory rate No significant changes were found in pulmonary function parameters such as middle air flow (MMEF). Conclusions Radiotherapy and chemotherapy can reduce pulmonary diffuse function in patients with esophageal cancer without any significant effect on the sub-function of the lungs, and will not increase the postoperative pulmonary complications.